ArticleJournal of animal science2025
Effects of Bacillus coagulans (GBI-30, 6086) supplementation on apparent total tract nutrient digestibility and the fecal characteristics and metabolites, immunity, and microbiota of healthy adult dogs.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Effects ofInternational journal of molecular sciences · 2026Article
- Effects ofMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bacillus coagulans GBI-30, 6086, is a lactic acid-producing, spore-forming bacteria with diverse characteristics that lend it resiliency through commercial pet food processing, storage, and chemical and enzymatic digestion through the gastrointestinal tract. The objective of this study was to determine the effects of B. coagulans on dietary apparent total tract nutrient digestibility (ATTD) and the hematology, immunoglobulin concentrations and fecal characteristics, metabolites, and microbiota populations of healthy adult dogs. Adult English Pointer dogs (n = 12; age = 5.9 ± 2.5 yr; body weight = 26.6 ± 6.1 kg) were fed the same diet but supplemented with B. coagulans or a placebo via gelatin capsules in a replicated 3 × 3 Latin square design. Capsules were administered daily before each feeding, with the following treatments tested: (1) basal diet + placebo (control; 250 mg maltodextrin); (2) basal diet + B. coagulans [low dose; 5 × 108 colony-forming units (CFU)/d]; and (3) basal diet + B. coagulans (high dose; 2.5 × 109 CFU/d). Fecal, blood, nasal, and pinnae samples were collected after a 22-d adaptation phase in each period. Data were analyzed using the Mixed Models procedure of SAS 9.4, with P < 0.05 being significant and P < 0.10 being trends. Bacillus coagulans supplementation did not affect ATTD, food intake, fecal metabolites, immunoglobulin concentrations, or hematology, but did lower fecal scores (P < 0.05; firmer stool). Using qPCR, fecal Faecalibacterium spp. abundance was greater (P < 0.05) and fecal Bacteroides spp., Bifidobacterium spp., and Ruminococcus gnavus abundances tended to be greater (P < 0.10) in dogs fed the low B. coagulans dose than those fed the placebo. Overall, our results demonstrate that this bacterial species can be safely supplemented to healthy dogs without a negative impact on nutrient digestibility or canine health parameters, and supplementation with the low dose treatment may help maintain fecal consistency and positively influence gastrointestinal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.